Document is current

Article History

Received: 28 February 2022

Accepted: 18 November 2022

First Online: 14 January 2023

Declarations

:

: This study was approved by the Institutional Review Board of Boston Children’s Hospital (DSC7903), which serves as IRB of record for all study sites. Informed consent was obtained from adult participants and/or a parent or legal guardian. Partipants age 7 and older with the cognitive capability to do so provided assent for study participation.

: No individual patient data are provided.

: Dr. Busch, Ms. Sonneborn, Ms. Hogue, Dr. Klaas, Dr. Srivastava, Dr. Hardan, Dr. Martinez-Agosto, and Dr. Eng declare that they have no competing interests.Dr. Frazier has received funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from the PTEN Research Foundation, SYNGAP Research Fund, Malan Syndrome Foundation, ADNP Kids Research Foundation, Quadrant Biosciences, Autism Speaks, Impel NeuroPharma, F. Hoffmann-La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, Roche Pharma, MaraBio, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in Autism EYES LLC.Dr. Sahin reports grant support from Novartis, Biogen, Astellas, Aeovian, Bridgebio, and Aucta. He has served on Scientific Advisory Boards for Novartis, Roche, Regenxbio, SpringWorks Therapeutics, Jaguar Therapeutics, and Alkermes, all unrelated to this project.